DexCom Inc (DXCM)vsHyperfine Inc (HYPR)
DXCM
DexCom Inc
$83.02
+0.44%
HEALTHCARE · Cap: $31.49B
HYPR
Hyperfine Inc
$0.96
-2.75%
HEALTHCARE · Cap: $94.69M
Smart Verdict
WallStSmart Research — data-driven comparison
DexCom Inc generates 32317% more annual revenue ($4.97B vs $15.33M). DXCM leads profitability with a 20.1% profit margin vs -226.9%. DXCM earns a higher WallStSmart Score of 72/100 (B).
DXCM
Strong Buy72
out of 100
Grade: B
HYPR
Avoid30
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 20 of every $100 in revenue as profit
Strong operational efficiency at 24.3%
Earnings expanding 43.6% YoY
Revenue surging 82.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 11.9x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -101.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : DXCM
The strongest argument for DXCM centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 20.1% and operating margin at 24.3%. Revenue growth of 13.1% demonstrates continued momentum.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 82.6% demonstrates continued momentum.
Bear Case : DXCM
The primary concerns for DXCM are PEG Ratio, P/E Ratio, Price/Book.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
DXCM profiles as a mature stock while HYPR is a hypergrowth play — different risk/reward profiles.
DXCM carries more volatility with a beta of 1.45 — expect wider price swings.
HYPR is growing revenue faster at 82.6% — sustainability is the question.
DXCM generates stronger free cash flow (449M), providing more financial flexibility.
Bottom Line
DXCM scores higher overall (72/100 vs 30/100), backed by strong 20.1% margins and 13.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DexCom Inc
HEALTHCARE · MEDICAL DEVICES · USA
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.
Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneering force in medical technology, renowned for developing the world’s first FDA-cleared portable MRI system, which significantly enhances diagnostic imaging accessibility at the point of care. By combining innovation with cost-efficiency, the company improves patient outcomes and facilitates rapid clinical decision-making. As healthcare continues to evolve, Hyperfine is strategically positioned to capture growth opportunities within the expanding imaging diagnostics market, presenting a compelling investment prospect for institutional investors focused on transformative healthcare solutions.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?